Retrospective analysis of 206 patients undergoing 215 consecutive bone marrow transplants (BMT) at St Jude Children's Research Hospital between November 1990 and December 1994 identified 6% (seven male, six female) with adenovirus infection. The affected patients had a median age of 7.9 years (range 3-24 years) at time of transplantation. Although transplants were performed for hematologic malignancies, solid tumors or nonmalignant conditions, only patients with hematologic malignancies had adenoviral infections. Adenovirus was first detected at a median of 54 days (range ؊4 to ؉333) after BMT. Adenovirus developed in eight of 69 (11.6%) patients receiving grafts from matched unrelated or mismatched related donors, in four of 52 (7.7%) receiving grafts from HLA-matched siblings, and in one of 93 (1.1%) receiving autografts. The most common manifestation of adenovirus infection was hemorrhagic cystitis, followed by gastroenteritis, pneumonitis and liver failure. The incidence of adenovirus infection in pediatric BMT patients at our institution is similar to that reported in adult patients. Using univariate analysis, use of total body irradiation and type of bone marrow graft were significant risk factors for adenovirus infection. Only use of total body irradiation remained as a factor on multiple logistic regression analysis.
results in systemic illness of greater severity and longer duration. In addition to the manifestations already described, adenovirus can cause hepatitis with or without hepatic necrosis, pancreatitis, nephritis and disseminated disease in immunodeficient hosts. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Consequently, mortality rates are high, ranging from 18 to 60%, with outcome dependent on patient age, type of immunosuppression, and adenovirus serotype. 3 Adenovirus infection in patients undergoing bone marrow transplantation, first described in 1985, can be severe with virus recoverable from many sites and often accompanied by significant morbidity and mortality. Adenovirus has been isolated in 5-20% of patients undergoing BMT and has been reported to cause invasive disease in 20% of these patients 18, 19 Recent studies have reported an increasing incidence of adenoviral infections, attributed to an increasing use of unrelated donor marrow transplantation. 19 Although published studies of adenovirus infection in BMT patients have included patients of all ages, adults have been the dominant age group. Adenovirus infection in children may differ from adults for several reasons. Children are more likely to have had a recent exposure and, therefore, are more likely to develop a primary infection. 1, 2 In addition, children are less likely than adults to suffer from immunosuppressive complications of BMT.
This paper reports the experience with adenovirus infection in 215 BMT performed in pediatric patients at St Jude Children's Research Hospital (SJCRH) between November 1990 and December 1994.
Patients and methods
Medical and clinical laboratory records of patients undergoing BMT at SJCRH between November 1990 and December 1994 (n ϭ 215) were analyzed retrospectively to identify patients with positive adenovirus cultures. Patient demographics, primary disease, type of BMT, preparatory regimen, clinical characteristics of the infection, antiviral therapy, and patient outcome were recorded.
Patients undergoing autologous BMT were conditioned with disease-specific chemotherapy without total body irradiation (TBI). Patients with acute myeloid leukemia undergoing autologous BMT received cyclophosphamide (200 mg/kg) and busulfan (16 mg/kg (GVHD) prophylaxis consisted of cyclosporine, started on day Ϫ2, with dosage adjustments to maintain plasma levels between 150 g/ml and 250 g/ml. Pentoxifylline was used in addition to cyclosporine in recipients of grafts from matched siblings. T lymphocyte depletion was performed on marrows from mismatched family members or matched unrelated donors using antibodies to CD3 in the presence of complement until March 1992, and antibodies to CD6 and CD8 in the presence of complement thereafter. [20] [21] [22] [23] Surveillance cultures for viral pathogens from the throat, nasopharynx, blood and rectum were obtained twice weekly during hospitalization. Tracheal and conjunctival culture specimens were obtained when clinically indicated. Biopsy and autopsy specimens of lung, liver, spleen and kidney were routinely sent for viral culture. Additional cultures were obtained when clinically indicated in outpatients. Patients with positive cultures had serial cultures obtained until negative.
Specimens for adenovirus detection were inoculated into A549 cell lines and observed for cytopathic effect for 2 weeks. Fluorescent antibody staining was used to confirm results of positive cultures.
Adenoviral disease was defined according to published criteria. 19 Definite disease was defined by a positive tissue culture from a sterile site (excluding the gastrointestinal tract), the presence of typical adenoviral nuclear inclusions on histopathology, or both in the presence of signs and symptoms compatible with adenoviral disease. Probable disease was defined as the presence of two or more positive cultures from other body sites in association with compatible symptoms without other identifiable cause.
Acute and chronic GVHD were graded according to published criteria. 24, 25 Mild acute GVHD was described as grades 0 or 1; moderate-to-severe acute GVHD was described as grades 2 to 4.
Only patients undergoing their initial BMT (n ϭ 206) were included in the statistical analysis of risk factors for adenovirus infection. Univariate analysis was performed to study the association between adenovirus infection and disease, type of BMT, acute GVHD, chronic GVHD, age, gender and TBI. Exact P values were calculated using the exact Pearson's 2 test. A multiple logistic regression model was fit to the data using a stepwise approach, in order to determine the effects of BMT type, acute GVHD, chronic GVHD, age at BMT, gender and TBI on adenovirus infection. Since all adenovirus patients belonged to one disease group (leukemia), disease type was not included in the model as a risk factor. Risk factors were entered into the model using a significance level of 0.1 and remained in the model if significant at ␣ level 0.05.
Results
Between November 1990 and December 1994, 215 consecutive BMTs were performed on 206 patients at SJCRH. Patients underwent bone marrow transplantation for a variety of diseases which included hematologic malignancies (n ϭ 150) and solid tumors (n ϭ 44), as well as other conditions (n ϭ 21), which included aplastic anemia, immunodeficiencies or metabolic disorders (Table 1) . Nine patients required a second BMT for loss of graft or disease recurrence.
Adenovirus was identified in 13 of 206 BMT patients undergoing 215 BMTs, yielding an incidence of 6% ( Table  1 ). The median age at BMT for patients with adenovirus infection was 7.9 years (range 3-24 years), with seven male and six female patients. All infected patients had a diagnosis of leukemia. All but one patient had undergone allogeneic BMT. Three of the infected patients had acute GVHD, while one had chronic GVHD.
Adenovirus was first detected at a median of 54 days (range Ϫ4 to ϩ333) after BMT ( Table 2) . Four patients developed adenoviral infection within the first 30 days, including one patient who had a positive stool culture during conditioning. Eight patients developed positive cultures within the first 100 days following BMT, compared with five patients more than 100 days following BMT. The median duration of culture positivity was 16 days (range 1-111 days). One patient had adenovirus first isolated at autopsy, and four patients continued to have positive cultures at the time of their deaths.
Adenovirus was isolated from a mean of 1.77 sites (median 1, range 1-4) per patient. The most common sites were the stool (eight patients) and urine (seven patients).
There were three patients with isolates from the throat or nasopharynx, two from the lower respiratory tract, two from the blood, and one from the liver. Eight patients were symptomatic at the time of adenovirus isolate and five were asymptomatic. One patient met the criteria for definite adenoviral disease ( Table 3 ). The patient's clinical course was complicated by hemorrhagic cystitis, pulmonary hemorrhage, gastrointestinal hemorrhage and liver failure. At autopsy adenovirus was isolated from urine, throat, blood and liver. Five patients (38.5%) had probable disseminated adenoviral disease. All of these patients had hemorrhagic cystitis with adenovirus isolated from the urine and one or more additional sites. The remaining seven patients had adenovirus isolated at a single site but did not meet the criteria for adenoviral disease. One patient each had adenovirus isolated only from nasopharynx, blood or urine. Four patients had adenovirus isolated from stool cultures only (Table 2) .
Of the seven patients with adenovirus isolated from the urine, six had hemorrhagic cystitis. Six patients had clinical gastroenteritis with adenovirus isolated in the stool, two had pulmonary disease with adenovirus isolated from bronchoalveolar lavage (BAL) washings, and one had hepatitis with adenovirus isolated from the liver at autopsy.
Eleven patients did not receive specific therapy. One patient received intravenous ribavirin as empiric therapy for pneumonitis, and a second for hemorrhagic cystitis. Both patients died of pneumonitis.
Seven of the 13 patients with adenoviral infection died, and autopsies were performed in four. One patient death, due to hepatic necrosis, was directly attributable to adenoviral disease. The patient who died of hepatic failure had both adenovirus and cytomegalovirus (CMV) isolated from the blood. Two patients died of pneumonitis, neither of whom had adenovirus isolated from their lungs. One of these two patients had hemorrhagic cystitis with adenovirus and mycoplasma isolated from the urine. Mycoplasma was also isolated from cultures of broncho-alveolar lavage (BAL) washings. The other patient had hemorrhagic cystitis with adenovirus isolated from urine and rectal cultures. One patient each died of relapse, Epstein-Barr virus (EBV)-induced lymphoproliferative disorder, Staphylococcus aureus sepsis and hepatic failure.
Adenovirus serotyping was performed in five patients.
Serotype 11 was most commonly identified, isolated in three patients. Other serotypes detected include serotype 5 in two patients and serotype 7 in one patient. One patient had both serotype 5 and 11 isolated. Table 4 shows risk factors for adenovirus infection. There were no significant differences with respect to age at BMT, gender or diagnosis. However, there were significant differences in the incidence of adenovirus infection in relation to BMT type and preparatory regimen. Patients with syngeneic or autologous BMTs had a lower incidence of adenovirus infection than did allogeneic recipients, while patients who received TBI as part of the preparatory regimen had a higher incidence of adenovirus infection compared to those who did not receive TBI. Results of the logistic regression analysis on the sample of 206 patients indicated that the use of TBI during the preparatory regimen had the most significant effect on adenovirus infection ( 2 ϭ 10.4, P value ϭ 0.002). Patients who had undergone TBI were 14 times more likely to get adenovirus infection in comparison to those who had not received TBI. There was not a significant difference in the incidence of adenovirus infection between recipients of unrelated or HLAmismatched grafts compared with related HLA-matched grafts. There was no statistically significant relationship between acute or chronic GVHD and adenovirus infection.
Discussion
Adenovirus infection in patients undergoing BMT is a significant cause of morbidity and mortality. Published studies have examined adenovirus infection in patient populations dominated by adults. We have reviewed 206 consecutive patients undergoing 215 BMT procedures over a 49 month period in a pediatric oncology hospital. The incidence of adenoviral infection in our pediatric population is comparable to that reported by investigators in Seattle. 18 In our series, allogeneic BMT and TBI were identified as significant risk factors for adenoviral infection.
Adenoviral infection in patients undergoing BMT has been a significant cause of morbidity and mortality, reported to have a mortality rate approaching 60%. 3 In this population, adenovirus infection leads to disseminated disease with myriad manifestations including hemorrhagic cystitis, pneumonia, nephritis, hepatitis, colitis and pancreatitis. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The incidence of adenovirus infection in BMT recipients has varied widely. In a review of 1051 patients from 6 to 55 years old undergoing autologous or allogeneic BMT for leukemia or aplastic anemia, the incidence of adenovirus infection was 4.9%. 18 More recently, in a review of 201 BMT recipients (118 adults, 83 pediatric), the incidence of adenovirus infection was 20.9%. 19 In this study infection was significantly more common in children than in adults (31.3 vs 13.6%). In our series, the incidence of adenovirus infection in pediatric patients is lower and is comparable to other reports.
In contrast to other reports, GVHD did not contribute to adenoviral infection in our patients. The incidence of moderate-to-severe GVHD among BMT patients was similar in our series to that reported by other investigators. 18, 19 280 JCML ϭ juvenile chronic myelogenous leukemia; ALL ϭ acute lymphocytic leukemia; AML ϭ acute myelocytic leukemia; CML ϭ chronic myelogenous leukemia; MUD ϭ matched unrelated donor; MS ϭ matched sibling; MMFM ϭ mismatched family member; AUTO ϭ autologous BMT; HC ϭ hemorrhagic cystitis; EBV-LPD ϭ Epstein-Barr virus-lymphoproliferative disorder. TBI ϭ total body irradiation; GVHD ϭ graft-versus-host disease; NS ϭ not significant.
In fact, no patient infected with adenovirus in our series had moderate to severe GVHD. In the Seattle series, 56% of their adenovirus-infected BMT patients had moderate to severe GVHD; in Milwaukee, moderate to severe GVHD was present in 21% of pediatric BMT patients and in 33% of adult BMT patients. The true incidence of adenovirus infection is likely to be underestimated in these reports owing to variation in viral culture surveillance during the transplant course. Furthermore, the assay used in this report is unable to detect serotypes 40 and 41, which are known to cause gastrointestinal disease. Serotype 41 is commonly detected in immunocompetent hosts. However, serotypes 40 and 41 have not been detected in BMT patients with adenovirus infection. 18, 19 Therefore, although it is probable that while severe adenoviral infections were detected, less severe illnesses may have escaped detection. Four of 13 patients in our series had gastrointestinal symptoms with adenovirus isolated in the stool.
The median time to onset of adenoviral detection following BMT was 54 days. In our study, only four patients developed adenovirus infection in the first 30 days following transplantation. These data contrast with another report which found that 50% of adenoviral infections in pediatric BMT recipients occurred within the first 30 days of the transplant course. 19 In our series, the number of adenoviral isolation sites per patient, the isolation sites and the serotypes isolated were consistent with other reports. Adenovirus was most commonly isolated from stool and urine specimens, which is also consistent with prior reports.
Adenovirus is a well known cause of hemorrhagic cystitis. This post-transplant complication is compounded by high-dose chemotherapy regimens containing cyclophosphamide. Serotypes 11 and 35 have a propensity for the urinary tract. 3, 9, 11, 13, 18 In the Milwaukee study, three patients developed hemorrhagic cystitis, two of whom were infected with serotype 35. 19 The most common clinical problem due to adenovirus infection in our series was hemorrhagic cystitis. All three patients in our study known to be infected with serotype 11 developed hemorrhagic cystitis.
Eight patients had gastroenteritis with adenovirus isolated from stool and one patient with hepatic necrosis had adenovirus found in the liver at autopsy. Only two patients in our study had adenovirus isolated from the lower respiratory tract. This contrasts with Seattle's experience, where adenovirus pneumonia represented the most common problem caused by adenovirus infection and was responsible for three deaths. This difference may reflect the higher incidence of acute GVHD in patients in the study from Seattle. 18 Reported risk factors for adenoviral infection in patients undergoing BMT include young age and moderate to severe acute GVHD. 18, 19 Our study was unable to confirm these risk factors; however, a TBI-containing preparatory regimen and allogeneic BMT were identified as significant risk factors.
Treatment options for adenoviral disease are limited. There are reports of ribavirin and ganciclovir having some clinical activity against adenoviral isolates.
26-29 However, there is no antiviral agent which has demonstrated in vitro activity against adenovirus. Some investigators have used intravenous immunoglobulin to treat immunocompromised patients with adenoviral infection. 30 Although attractive, this option is unlikely to work since immunocompetent donors are unlikely to have significant amounts of antibody against serotypes 11, 34 or 35. Cytotoxic lymphocytes have been demonstrated to be effective against disease caused by EBV and cytomegalovirus in BMT recipients. [31] [32] [33] However, the multiple adenoviral serotypes may make the generation of virus-specific cytotoxic lymphocytes difficult. There has been one case report of successful treatment of disseminated adenoviral disease in a BMT patient using donor leukocyte infusions. 34 Adenovirus infection in patients undergoing BMT results in significant morbidity and mortality. Our series identified adenovirus infection in 6% of 215 pediatric BMTs performed. We were unable to confirm an earlier study which found an incidence of adenoviral infection of 31% in pediatric BMT recipients. In our series, patients undergoing allogeneic BMT or those conditioned with a TBI-containing preparatory regimen are at significantly increased risk for adenovirus infection. Adenoviral disease will pose a challenge for clinicians, who still have no effective therapy for this illness.
